JPWO2021021963A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021021963A5
JPWO2021021963A5 JP2022506145A JP2022506145A JPWO2021021963A5 JP WO2021021963 A5 JPWO2021021963 A5 JP WO2021021963A5 JP 2022506145 A JP2022506145 A JP 2022506145A JP 2022506145 A JP2022506145 A JP 2022506145A JP WO2021021963 A5 JPWO2021021963 A5 JP WO2021021963A5
Authority
JP
Japan
Prior art keywords
cells
antigen
cell composition
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542321A5 (https=
JP2022542321A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044117 external-priority patent/WO2021021963A1/en
Publication of JP2022542321A publication Critical patent/JP2022542321A/ja
Publication of JP2022542321A5 publication Critical patent/JP2022542321A5/ja
Publication of JPWO2021021963A5 publication Critical patent/JPWO2021021963A5/ja
Priority to JP2025105888A priority Critical patent/JP2025156345A/ja
Withdrawn legal-status Critical Current

Links

JP2022506145A 2019-07-29 2020-07-29 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 Withdrawn JP2022542321A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025105888A JP2025156345A (ja) 2019-07-29 2025-06-23 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962880044P 2019-07-29 2019-07-29
US62/880,044 2019-07-29
US201962892779P 2019-08-28 2019-08-28
US62/892,779 2019-08-28
US202062960507P 2020-01-13 2020-01-13
US62/960,507 2020-01-13
PCT/US2020/044117 WO2021021963A1 (en) 2019-07-29 2020-07-29 Nk cell composition and preparations for immunotherapy and methods for their production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025105888A Division JP2025156345A (ja) 2019-07-29 2025-06-23 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法

Publications (3)

Publication Number Publication Date
JP2022542321A JP2022542321A (ja) 2022-09-30
JP2022542321A5 JP2022542321A5 (https=) 2023-08-07
JPWO2021021963A5 true JPWO2021021963A5 (https=) 2023-08-07

Family

ID=74228666

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506145A Withdrawn JP2022542321A (ja) 2019-07-29 2020-07-29 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法
JP2025105888A Pending JP2025156345A (ja) 2019-07-29 2025-06-23 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025105888A Pending JP2025156345A (ja) 2019-07-29 2025-06-23 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法

Country Status (10)

Country Link
US (1) US20220275334A1 (https=)
EP (1) EP4004193A4 (https=)
JP (2) JP2022542321A (https=)
KR (1) KR20220038450A (https=)
CN (1) CN114466924A (https=)
AU (1) AU2020321953A1 (https=)
CA (1) CA3145510A1 (https=)
IL (1) IL290080A (https=)
MX (1) MX2022001257A (https=)
WO (1) WO2021021963A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3125503A1 (en) * 2019-01-18 2020-07-23 Acepodia Biotechnologies Ltd. A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP4127188A4 (en) * 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
CN113402620B (zh) * 2021-07-30 2021-12-10 中山大学 细胞因子联合嵌合抗原受体的融合蛋白及其应用
CN118119636A (zh) * 2021-08-10 2024-05-31 盖米达细胞有限公司 抗her2 car nk细胞、它们的生产方法及其用途
US20250017964A1 (en) * 2021-11-15 2025-01-16 City Of Hope Engineering or inducing pdgf and/or pdgfr signaling to enhance nk cell therapy
CN114891744B (zh) * 2022-07-13 2022-10-25 山东省齐鲁干细胞工程有限公司 一种冷冻脐带血nk细胞体外扩增方法
WO2024047368A1 (en) * 2022-09-02 2024-03-07 Imperial College Innovations Limited Natural killer cells
WO2024113294A1 (zh) * 2022-12-01 2024-06-06 血霁生物科技(上海)有限公司 一种分化nk细胞的方法、培养基及其应用
CN115927180A (zh) * 2022-12-01 2023-04-07 血霁生物科技(上海)有限公司 一种分化nk细胞的方法、培养基及其应用
CN116769722B (zh) * 2023-07-04 2024-07-16 杭州荣谷生物科技有限公司 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用
CN116983409B (zh) * 2023-07-17 2025-11-14 中国检验检疫科学研究院 一种抑制寨卡病毒的方法及其应用
CN118853562B (zh) * 2024-07-11 2025-08-29 中国科学院广州生物医药与健康研究院 一种靶向cd19的car-nk细胞及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130095079A1 (en) * 2010-04-09 2013-04-18 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
GB201216649D0 (en) * 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
US20200163993A1 (en) * 2017-05-09 2020-05-28 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes

Similar Documents

Publication Publication Date Title
Liu et al. NK cell-based cancer immunotherapy: from basic biology to clinical development
Hu et al. Natural killer cell-based immunotherapy for cancer: advances and prospects
Dianat‐Moghadam et al. Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells
US12478672B2 (en) Use of triplex CMV vaccine in CAR T cell therapy
Dahlberg et al. Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity
Pittari et al. Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies
Bernareggi et al. Development of innate immune cells from human pluripotent stem cells
Zhu et al. Concise review: human pluripotent stem cells to produce cell-based cancer immunotherapy
WO2019138217A1 (en) Method for transducing cells with a viral vector for the expression of a chimeric antigen receptor (car) or transgenic t-cell receptor (tcr)
JPWO2021021963A5 (https=)
RU2015140811A (ru) Композиции и способы иммунотерапии
Shook et al. Natural killer cell engineering for cellular therapy of cancer
Mazza et al. Prospects for development of induced pluripotent stem cell-derived CAR-targeted immunotherapies
Van Caeneghem et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities
JP2023538463A (ja) がん及び自己免疫疾患及び炎症性疾患を治療する方法
US20220056411A1 (en) Methods for isolating cd8+ selected t cells
CA3235379A1 (en) Engineering stem cell t cells with multiple t cell receptors
Lankester et al. Will post-transplantation cell therapies for pediatric patients become standard of care?
Sahin et al. Natural killer cell-mediated cellular therapy of hematological malignancies
CN121773194A (zh) 培养γδT细胞的方法
US20250090581A1 (en) Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use
US20240240148A1 (en) Engineering stem cells for allogenic car t cell therapies
US20240271095A1 (en) Production of engineered t cells from stem cells
Kühnel et al. Engineered Natural Killer Cell Lines and Their Application for Cancer Immunotherapy
Leuci et al. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy